In recent years, transformative strides in the treatment of sickle cell disease (SCD) have materialized with the FDA’s approval of groundbreaking cell-based gene therapies. Notably, in December 2023, the FDA granted approval for Casgevy from Vertex Pharmaceuticals and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Therapeutics ...
read more